Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.62 |
| ▸ | CA2 | P00918 | 6/20 | 0.62 |
| ▸ | CA9 | Q16790 | 6/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281254 | 0.84 | CA12 (0.54) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL17790966 | 0.78 | CA12 (0.57) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL9284900 | 0.78 | CA12 (0.61) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL10907109 | 0.78 | ALOX15 (0.69) | LMNAMAPTTP53NPC1HDAC4 | |
| SCHEMBL12266930 | 0.76 | FLT1 (0.51) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL10263007 | 0.74 | CA12 (0.57) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL1360325 | 0.74 | CA12 (0.62) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL7902821 | 0.74 | CA12 (0.57) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL1169513 | 0.74 | CA12 (0.57) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL5586085 | 0.74 | ALOX15 (0.60) | CA12CA2CA9CA1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CA12 3489/4885CA2 985/4885CA9 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.